Kubiak, Grzegorz M. and Kwieciński, Radosław and Ciarka, Agnieszka and Tukiendorf, Andrzej and Przybyłowski, Piotr and Hrapkowicz, Tomasz and Zembala, Michał O. (2020) The Impact of Beta Blockers on Survival in Heart Transplant Recipients: Insights from the Zabrze HTx Registry. Cardiology Research and Practice, 2020. pp. 1-7. ISSN 2090-8016
5190248.pdf - Published Version
Download (1MB)
Abstract
Introduction. The data assessing the impact of beta blocker (BB) medication on survival in patients after heart transplantation (HTx) are scarce and unequivocal; therefore, we investigated this population. Methods. We retrospectively analyzed the HTx Zabrze Registry of 380 consecutive patients who survived the 30-day postoperative period. Results. The percentage of patients from the entire cohort taking BBs was as follows: atenolol 24 (17%), bisoprolol 67 (49%), carvedilol 11 (8%), metoprolol 28 (20%), and nebivolol 8 (6%). The patients receiving BBs were older (56.94 ± 14.68 years vs. 52.70 ± 15.35 years, ) and experienced an onset of HTx earlier in years (11.65 ± 7.04 vs. 7.24 ± 5.78 ). They also had higher hematocrit (0.40 ± 0.05 vs. 0.39 ± 0.05, ) and red blood cells (4.63 (106/μl) ± 0.71 vs. 4.45 (106/μl) ± 0.68, ). Survival according to BB medication did not differ among the groups () (log-rank test). Univariate Cox proportional hazard regression analysis revealed that the following parameters were associated with unfavorable diagnosis: serum concentration of albumin (g/l) HR: 0.87, 95% CI (0.81–0.94), ; fibrinogen (mg/dl) HR: 1.006, 95% CI (1.002–1.008), ; and C-reactive protein (mg/l) HR: 1.014, 95% CI (1.004–1.023), . Conclusions. The use of BBs in our cohort of patients after HTx was not associated with survival benefits.
Item Type: | Article |
---|---|
Subjects: | Journal Eprints > Medical Science |
Depositing User: | Managing Editor |
Date Deposited: | 11 Feb 2023 06:02 |
Last Modified: | 18 Jun 2024 06:46 |
URI: | http://repository.journal4submission.com/id/eprint/601 |